Search Results for medicines

Tahoe Therapeutics Secures $30M to Develop World’s Largest Human Cell AI Training Dataset

Tahoe Therapeutics Secures $30 Million to Build the World’s Largest Dataset for Training AI-Powered Human Cell Models, Aiming to Transform Precision Medicine Tahoe Therapeutics, a biotechnology company at the intersection of artificial intelligence and cellular biology, has announced the successful…

Read MoreTahoe Therapeutics Secures $30M to Develop World’s Largest Human Cell AI Training Dataset

Stoke, Biogen Dose First Patient in Phase 3 EMPEROR Trial for Dravet Therapy

Stoke Therapeutics and Biogen Dose First Patient in Pivotal Phase 3 EMPEROR Study of Zorevunersen, an Investigational Disease-Modifying Therapy for Dravet Syndrome Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering RNA-based medicines to restore protein expression, and Biogen Inc.…

Read MoreStoke, Biogen Dose First Patient in Phase 3 EMPEROR Trial for Dravet Therapy

Rocket Pharmaceuticals Announces Q2 2025 Financial Results and Key Business Milestones

Rocket Pharmaceuticals Announces Second Quarter 2025 Results, Reshapes Strategic Focus Around Cardiovascular Gene Therapy Platform, and Advances Late-Stage Pipeline Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company developing a sustainable portfolio of genetic therapies for rare disorders…

Read MoreRocket Pharmaceuticals Announces Q2 2025 Financial Results and Key Business Milestones

Roche’s Susvimo Preserves Vision for 5 Years with Twice-Yearly Dosing in nAMD

Roche’s Susvimo Shows Durable Vision Preservation Over Five Years with Twice-Yearly Treatment in Neovascular AMD Roche has released compelling new long-term data highlighting the extended efficacy, safety, and durability of its innovative eye implant therapy, Susvimo® (ranibizumab injection), for individuals…

Read MoreRoche’s Susvimo Preserves Vision for 5 Years with Twice-Yearly Dosing in nAMD
Arrowhead

Arrowhead’s Subsidiary Visirna Sells China Rights for Plozasiran to Sanofi

Arrowhead’s Subsidiary Visirna Transfers Greater China Rights to Plozasiran to Sanofi in Strategic $395 Million Deal Amid Regulatory Milestone in Hypertriglyceridemia In a move poised to reshape the therapeutic landscape for patients with severe lipid disorders in China, Arrowhead Pharmaceuticals,…

Read MoreArrowhead’s Subsidiary Visirna Sells China Rights for Plozasiran to Sanofi

EC Approves CAR-T Therapy Using AGC Biologics’ Lentiviral Vectors

European Commission Greenlights AUCATZYL®: AGC Biologics Marks 10th Regulatory Approval with Autolus’ CAR-T Therapy AGC Biologics, a global contract development and manufacturing organization (CDMO) specializing in biologics and advanced therapies, has reached another significant milestone. On July 21, the European…

Read MoreEC Approves CAR-T Therapy Using AGC Biologics’ Lentiviral Vectors

Altasciences and VoxCell Partner to Boost Preclinical Drug Development

Altasciences and VoxCell BioInnovation Forge Strategic Partnership to Revolutionize Preclinical Drug Development with 3D Bioprinted Human Tissue Models In a move poised to reshape the landscape of early-stage drug development, Altasciences, a fully integrated drug development solution provider, and VoxCell…

Read MoreAltasciences and VoxCell Partner to Boost Preclinical Drug Development
BeOne

BeOne’s BGB-16673 Earns EMA PRIME Status for Waldenstrom’s Macroglobulinemia

BeOne Medicines Achieves Key Regulatory Milestone as EMA Grants PRIME Designation to BTK Degrader BGB-16673 for Waldenstrom’s Macroglobulinemia BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), an emerging global player in oncology therapeutics, has reached a critical milestone in…

Read MoreBeOne’s BGB-16673 Earns EMA PRIME Status for Waldenstrom’s Macroglobulinemia

Actio Biosciences Secures FDA IND Clearance and Fast Track for ABS-1230 in KCNT1 Epilepsy

Actio Biosciences Receives FDA IND Clearance and Fast Track Designation for ABS-1230 in KCNT1-Related Epilepsy, Marking Major Advancement in Pediatric Precision Medicine Actio Biosciences, a clinical-stage biotechnology company pioneering novel therapies through the lens of genetics and precision medicine, has…

Read MoreActio Biosciences Secures FDA IND Clearance and Fast Track for ABS-1230 in KCNT1 Epilepsy
Grifols

Grifols Posts €3.68B Revenue and €177M Profit in H1 2025, Advancing Value Creation Plan

Grifols Reports Strong First Half 2025 Results with Robust Revenue Growth, Rising Profitability, and Strategic Progress Across Business Units Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and a world leader in plasma-derived medicines, has announced a strong set of…

Read MoreGrifols Posts €3.68B Revenue and €177M Profit in H1 2025, Advancing Value Creation Plan